Global Predictive Genetic Testing and Consumer Genomics Market By Type (Predictive Testing (Presymptomatic Testing, Predispositional Testing), Consumer Genomics), By Application (Cardiovascular Diseases, Pregnancy care, Breast and Ovarian Cancer, Prostate cancer, Colon Cancer, Neurogenetics, Ocular Diseases, Diabetic Screening and Monitoring, Hereditary Cancer, Others), By Setting Type (Direct to Consumer (DTC), Clinics, Hospitals, Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Predictive genetic testing is the use of a genetic test in an asymptomatic person to predict future illness risk. These tests are part of a new and rapidly expanding class of medical tests that are fundamentally different from traditional medical diagnostic examinations. Genetic testing provides details information about a person's genetic history. Newborn screening, carrier testing, prenatal testing, preimplantation testing, predictive and presymptomatic testing, forensic testing, and additional types of genetic testing are among them. Gene mutations associated with illnesses that occur after birth, frequently later in life, are detected using predictive and presymptomatic testing methods. These tests can be useful for persons who have a family relative who has a genetic illness but doesn’t exhibit any symptoms of the disorder at the time of testing. Predictive testing can detect mutations that raise a person's chance of acquiring genetic illnesses, such as cancer. The predictive genetic testing and consumer genomics market is driven by the increasing prevalence of cardiovascular disease such as diabetes, and genetic disorders around the globe aids the market growth. For instance, according to the International Diabetes Federation Organizations, diabetes affected about 537 million people (20-79 years) in 2021. By 2030, the overall number of diabetics is projected to reach 643 million, and by 2045, it will reach 783 million. Furthermore, growing awareness of the benefits of predictive genetic testing, as well as the development of Next-generation Platform Sequencing (NGS), will drive market expansion in the future. However, the market will be limited by the rising expense of genomic research equipment, as well as the difficulties of predicting genetic testing and consumer/wellness genomics.
The coronavirus disease 2019 pandemic, caused by the SARS-CoV-2 coronavirus, has resulted in a worldwide and local health disaster. Various government bodies imposed harsh lockdowns in try to stop the spread of the disease. COVID-19 clinical investigations have shown clinical risk factors for severe diseases such as age, gender, obesity, and comorbidities. Individual responses to viruses, particularly SARS-CoV-2, may be influenced by gene polymorphism. The candidate gene technique is an important method for discovering genetic risk factors for complicated illnesses such as severe COVID-19. Furthermore, the enhanced promise of innovation in testing equipment and treatment will provide new opportunities for the predictive genetic testing and consumer genomics market in the healthcare sector to expand in the near future.
In terms of revenue, the predictive genetic testing and consumer genomics market was valued at US$ 5,090.4 Mn in 2021 and is expected to reach US$ 16,644.7 Mn by 2030 growing at a CAGR of 14.0% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Predictive Genetic Testing and Consumer Genomics Market Revenue & Forecast, (US$ Million), 2015 – 2030
Type Outlook
Based on type, the global predictive genetic testing and consumer genomics market has been primarily segmented into predictive testing and consumer genomics. The predictive testing segment held the highest share in the market in 2021 owing to the growing cases of cancer across the world. Furthermore, the availability of multigene panels for detecting various gene mutations or variants has also accelerated the adoption of susceptibility tests, resulting in increased segment growth.
Application Outlook
Based on application, the global predictive genetic testing and consumer genomics market has been segmented into cardiovascular diseases, pregnancy care, breast and ovarian cancer, prostate cancer, colon cancer, neurogenetics, ocular diseases, diabetic screening and monitoring, hereditary cancer, and others. Among the application, prostate cancer is projected to be the fastest-growing segment over the forecast period. Prostate cancer develops in the prostate. The prostate is a small walnut-shaped gland in males that generates seminal fluid, which feeds and transports sperm. According to the American Cancer Society, the annual rate of new prostate cancer cases was 112.7 per 100,000 men. The annual death rate for men was 18.9 per 100,000.
Setting Type Outlook
Based on setting type, the global predictive genetic testing and consumer genomics market has been segmented into direct to consumer (DTC), clinics, hospitals, and others. Direct to consumer (DTC) segment held the highest share in the market in 2021. The increased availability of direct-to-consumer tests at affordable pricing, as well as growing patient awareness of DTC testing methodologies, are drivers driving segment expansion in the market. These genetic tests are sold directly to customers through television, and print advertisements, and can be purchased online or in stores. Direct-to-consumer genetic testing allows people to get their genetic information without having to go through a healthcare professional or health insurance organization.
Region Outlook
Based on regions, North America held the highest share of the worldwide predictive genetic testing and consumer genomics market in 2021, owing to increased research & development in this region and increased awareness among the people related to genetic testing. Furthermore, the availability of advanced technologies and the presence of major players in this region contribute to the growth of the North America region in the market.
Competitive Landscape
The report provides both, qualitative and quantitative research of predictive genetic testing and consumer genomics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the predictive genetic testing and consumer genomics market are listed below:
- 23andMe, Inc.
- Abbott
- Agilent Technologies, Inc.
- Avellino.com
- BGI
- Color Health, Inc.
- F. Hoffmann-La Roche Ltd
- Gene by Gene, Ltd.
- Illumina, Inc.
- Labcorp.
- Mapmygenome
- Myriad Genetics, Inc.
- Quest Diagnostics, Inc.
- Thermo Fisher Scientific
- Other Market Participants
Global Predictive Genetic Testing and Consumer Genomics Market:
- By Type
- Predictive Testing
- Presymptomatic Testing
- Predispositional Testing
- Consumer Genomics
- Predictive Testing
- By Application
- Cardiovascular Diseases
- Pregnancy care
- Breast and Ovarian Cancer
- Prostate cancer
- Colon Cancer
- Neurogenetics
- Ocular Diseases
- Diabetic Screening and Monitoring
- Hereditary Cancer
- Others
- By Setting Type
- Direct to Consumer (DTC)
- Clinics
- Hospitals
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2021
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Predictive Genetic Testing And Consumer
Genomics Market
6. Market Synopsis:
Predictive Genetic Testing And Consumer Genomics Market
7. Predictive Genetic Testing And Consumer Genomics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Predictive Genetic Testing And Consumer Genomics Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Predictive Genetic Testing And Consumer
Genomics Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Predictive Genetic Testing And Consumer Genomics Market
8. Global Predictive Genetic Testing And Consumer Genomics Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn)
8.2. Global
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
8.2.1. Predictive
Testing (Definition, Market Estimation and Penetration, 2015 - 2021, Market
Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Presymptomatic Testing,
Predispositional Testing)
8.2.1.1. Presymptomatic Testing
8.2.1.2. Predispositional Testing
8.2.2. Consumer
Genomics
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By Type
9. Global Predictive Genetic Testing And Consumer Genomics Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
9.2.1. Cardiovascular
Diseases
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Pregnancy
care
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.2.3. Breast
and Ovarian Cancer
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2021
9.2.3.3. Market Forecast, 2022 - 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 - 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 - 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 - 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 - 2030
9.2.4. Prostate
cancer
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2021
9.2.4.3. Market Forecast, 2022 - 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 - 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 - 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 - 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 - 2030
9.2.5. Colon
Cancer
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2021
9.2.5.3. Market Forecast, 2022 - 2030
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 - 2030
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 - 2030
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 - 2030
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 - 2030
9.2.6. Neurogenetics
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2021
9.2.6.3. Market Forecast, 2022 - 2030
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2021
9.2.6.5.1.2. Market
Forecast, 2022 - 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2021
9.2.6.5.2.2. Market
Forecast, 2022 - 2030
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2021
9.2.6.5.3.2. Market
Forecast, 2022 - 2030
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2021
9.2.6.5.4.2. Market
Forecast, 2022 - 2030
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2021
9.2.6.5.5.2. Market
Forecast, 2022 - 2030
9.2.7. Ocular
Diseases
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2021
9.2.7.3. Market Forecast, 2022 - 2030
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market
Estimation, 2015 - 2021
9.2.7.5.1.2. Market
Forecast, 2022 - 2030
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2021
9.2.7.5.2.2. Market
Forecast, 2022 - 2030
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2021
9.2.7.5.3.2. Market
Forecast, 2022 - 2030
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2021
9.2.7.5.4.2. Market
Forecast, 2022 - 2030
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market
Estimation, 2015 - 2021
9.2.7.5.5.2. Market
Forecast, 2022 - 2030
9.2.8. Diabetic
Screening and Monitoring
9.2.8.1. Definition
9.2.8.2. Market Estimation and Penetration, 2015 - 2021
9.2.8.3. Market Forecast, 2022 - 2030
9.2.8.4. Compound Annual Growth Rate (CAGR)
9.2.8.5. Regional Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1. Market
Estimation, 2015 - 2021
9.2.8.5.1.2. Market
Forecast, 2022 - 2030
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2015 - 2021
9.2.8.5.2.2. Market
Forecast, 2022 - 2030
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1. Market
Estimation, 2015 - 2021
9.2.8.5.3.2. Market
Forecast, 2022 - 2030
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1. Market
Estimation, 2015 - 2021
9.2.8.5.4.2. Market
Forecast, 2022 - 2030
9.2.8.5.5. Latin America
9.2.8.5.5.1. Market
Estimation, 2015 - 2021
9.2.8.5.5.2. Market
Forecast, 2022 - 2030
9.2.9. Hereditary
Cancer
9.2.9.1. Definition
9.2.9.2. Market Estimation and Penetration, 2015 - 2021
9.2.9.3. Market Forecast, 2022 - 2030
9.2.9.4. Compound Annual Growth Rate (CAGR)
9.2.9.5. Regional Bifurcation
9.2.9.5.1. North America
9.2.9.5.1.1. Market
Estimation, 2015 - 2021
9.2.9.5.1.2. Market
Forecast, 2022 - 2030
9.2.9.5.2. Europe
9.2.9.5.2.1. Market
Estimation, 2015 - 2021
9.2.9.5.2.2. Market
Forecast, 2022 - 2030
9.2.9.5.3. Asia Pacific
9.2.9.5.3.1. Market
Estimation, 2015 - 2021
9.2.9.5.3.2. Market
Forecast, 2022 - 2030
9.2.9.5.4. Middle East and Africa
9.2.9.5.4.1. Market
Estimation, 2015 - 2021
9.2.9.5.4.2. Market
Forecast, 2022 - 2030
9.2.9.5.5. Latin America
9.2.9.5.5.1. Market
Estimation, 2015 - 2021
9.2.9.5.5.2. Market
Forecast, 2022 - 2030
9.2.10. Others
9.2.10.1. Definition
9.2.10.2. Market Estimation and Penetration, 2015 - 2021
9.2.10.3. Market Forecast, 2022 - 2030
9.2.10.4. Compound Annual Growth Rate (CAGR)
9.2.10.5. Regional Bifurcation
9.2.10.5.1. North America
9.2.10.5.1.1. Market
Estimation, 2015 - 2021
9.2.10.5.1.2. Market
Forecast, 2022 - 2030
9.2.10.5.2. Europe
9.2.10.5.2.1. Market
Estimation, 2015 - 2021
9.2.10.5.2.2. Market
Forecast, 2022 - 2030
9.2.10.5.3. Asia Pacific
9.2.10.5.3.1. Market
Estimation, 2015 - 2021
9.2.10.5.3.2. Market
Forecast, 2022 - 2030
9.2.10.5.4. Middle East and Africa
9.2.10.5.4.1. Market
Estimation, 2015 - 2021
9.2.10.5.4.2. Market
Forecast, 2022 - 2030
9.2.10.5.5. Latin America
9.2.10.5.5.1. Market
Estimation, 2015 - 2021
9.2.10.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Predictive Genetic Testing And Consumer Genomics Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
10.2.1. Direct
to Consumer (DTC)
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Clinics
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.2.3. Hospitals
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2021
10.2.4.3. Market Forecast, 2022 - 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By
Setting Type
11. North America Predictive Genetic Testing And Consumer
Genomics Market Analysis and Forecasts, 2022
- 2030
11.1. Overview
11.1.1. North
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn)
11.2. North
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
11.2.1. Predictive
Testing
11.2.1.1. Presymptomatic Testing
11.2.1.2. Predispositional Testing
11.2.2. Consumer
Genomics
11.3. North
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
11.3.1. Cardiovascular
Diseases
11.3.2. Pregnancy
care
11.3.3. Breast
and Ovarian Cancer
11.3.4. Prostate
cancer
11.3.5. Colon Cancer
11.3.6. Neurogenetics
11.3.7. Ocular
Diseases
11.3.8. Diabetic
Screening and Monitoring
11.3.9. Hereditary
Cancer
11.3.10. Others
11.4. North
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
11.4.1. Direct
to Consumer (DTC)
11.4.2. Clinics
11.4.3. Hospitals
11.4.4. Others
11.5. North
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Country
11.5.1. U.S
11.5.1.1. U.S Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.1.1.1. Predictive Testing
11.5.1.1.1.1. Presymptomatic
Testing
11.5.1.1.1.2. Predispositional
Testing
11.5.1.1.2. Consumer Genomics
11.5.1.2. U.S Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.1.2.1. Cardiovascular Diseases
11.5.1.2.2. Pregnancy care
11.5.1.2.3. Breast and Ovarian Cancer
11.5.1.2.4. Prostate cancer
11.5.1.2.5. Colon Cancer
11.5.1.2.6. Neurogenetics
11.5.1.2.7. Ocular Diseases
11.5.1.2.8. Diabetic Screening and Monitoring
11.5.1.2.9. Hereditary Cancer
11.5.1.2.10.
Others
11.5.1.3. U.S Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
11.5.1.3.1. Direct to Consumer (DTC)
11.5.1.3.2. Clinics
11.5.1.3.3. Hospitals
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1. Canada Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.2.1.1. Predictive Testing
11.5.2.1.1.1. Presymptomatic
Testing
11.5.2.1.1.2. Predispositional
Testing
11.5.2.1.2. Consumer Genomics
11.5.2.2. Canada Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.2.2.1. Cardiovascular Diseases
11.5.2.2.2. Pregnancy care
11.5.2.2.3. Breast and Ovarian Cancer
11.5.2.2.4. Prostate cancer
11.5.2.2.5. Colon Cancer
11.5.2.2.6. Neurogenetics
11.5.2.2.7. Ocular Diseases
11.5.2.2.8. Diabetic Screening and Monitoring
11.5.2.2.9. Hereditary Cancer
11.5.2.2.10.
Others
11.5.2.3. Canada Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
11.5.2.3.1. Direct to Consumer (DTC)
11.5.2.3.2. Clinics
11.5.2.3.3. Hospitals
11.5.2.3.4. Others
11.5.3. Mexico
11.5.3.1. Mexico Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
11.5.3.1.1. Predictive Testing
11.5.3.1.1.1. Presymptomatic
Testing
11.5.3.1.1.2. Predispositional
Testing
11.5.3.1.2. Consumer Genomics
11.5.3.2. Mexico Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.3.2.1. Cardiovascular Diseases
11.5.3.2.2. Pregnancy care
11.5.3.2.3. Breast and Ovarian Cancer
11.5.3.2.4. Prostate cancer
11.5.3.2.5. Colon Cancer
11.5.3.2.6. Neurogenetics
11.5.3.2.7. Ocular Diseases
11.5.3.2.8. Diabetic Screening and Monitoring
11.5.3.2.9. Hereditary Cancer
11.5.3.2.10.
Others
11.5.3.3. Mexico Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
11.5.3.3.1. Direct to Consumer (DTC)
11.5.3.3.2. Clinics
11.5.3.3.3. Hospitals
11.5.3.3.4. Others
11.5.4. Rest of
North America
11.5.4.1. Rest of North America Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
11.5.4.1.1. Predictive Testing
11.5.4.1.1.1. Presymptomatic
Testing
11.5.4.1.1.2. Predispositional
Testing
11.5.4.1.2. Consumer Genomics
11.5.4.2. Rest of North America Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.4.2.1. Cardiovascular Diseases
11.5.4.2.2. Pregnancy care
11.5.4.2.3. Breast and Ovarian Cancer
11.5.4.2.4. Prostate cancer
11.5.4.2.5. Colon Cancer
11.5.4.2.6. Neurogenetics
11.5.4.2.7. Ocular Diseases
11.5.4.2.8. Diabetic Screening and Monitoring
11.5.4.2.9. Hereditary Cancer
11.5.4.2.10.
Others
11.5.4.3. Rest of North America Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
11.5.4.3.1. Direct to Consumer (DTC)
11.5.4.3.2. Clinics
11.5.4.3.3. Hospitals
11.5.4.3.4. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By Type
11.6.3. By
Application
11.6.4. By
Setting Type
12. Europe Predictive Genetic Testing And Consumer Genomics Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn)
12.2. Europe
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
12.2.1. Predictive
Testing
12.2.1.1. Presymptomatic Testing
12.2.1.2. Predispositional Testing
12.2.2. Consumer
Genomics
12.3. Europe
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
12.3.1. Cardiovascular
Diseases
12.3.2. Pregnancy
care
12.3.3. Breast
and Ovarian Cancer
12.3.4. Prostate
cancer
12.3.5. Colon
Cancer
12.3.6. Neurogenetics
12.3.7. Ocular
Diseases
12.3.8. Diabetic
Screening and Monitoring
12.3.9. Hereditary
Cancer
12.3.10. Others
12.4. Europe
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
12.4.1. Direct
to Consumer (DTC)
12.4.2. Clinics
12.4.3. Hospitals
12.4.4. Others
12.5. Europe
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.1. France
12.5.1.1. France Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.1.1.1. Predictive Testing
12.5.1.1.1.1. Presymptomatic
Testing
12.5.1.1.1.2. Predispositional
Testing
12.5.1.1.2. Consumer Genomics
12.5.1.2. France Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.1.2.1. Cardiovascular Diseases
12.5.1.2.2. Pregnancy care
12.5.1.2.3. Breast and Ovarian Cancer
12.5.1.2.4. Prostate cancer
12.5.1.2.5. Colon Cancer
12.5.1.2.6. Neurogenetics
12.5.1.2.7. Ocular Diseases
12.5.1.2.8. Diabetic Screening and Monitoring
12.5.1.2.9. Hereditary Cancer
12.5.1.2.10.
Others
12.5.1.3. France Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
12.5.1.3.1. Direct to Consumer (DTC)
12.5.1.3.2. Clinics
12.5.1.3.3. Hospitals
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1. The UK Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.2.1.1. Predictive Testing
12.5.2.1.1.1. Presymptomatic
Testing
12.5.2.1.1.2. Predispositional
Testing
12.5.2.1.2. Consumer Genomics
12.5.2.2. The UK Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.2.2.1. Cardiovascular Diseases
12.5.2.2.2. Pregnancy care
12.5.2.2.3. Breast and Ovarian Cancer
12.5.2.2.4. Prostate cancer
12.5.2.2.5. Colon Cancer
12.5.2.2.6. Neurogenetics
12.5.2.2.7. Ocular Diseases
12.5.2.2.8. Diabetic Screening and Monitoring
12.5.2.2.9. Hereditary Cancer
12.5.2.2.10.
Others
12.5.2.3. The UK Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
12.5.2.3.1. Direct to Consumer (DTC)
12.5.2.3.2. Clinics
12.5.2.3.3. Hospitals
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1. Spain Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.3.1.1. Predictive Testing
12.5.3.1.1.1. Presymptomatic
Testing
12.5.3.1.1.2. Predispositional
Testing
12.5.3.1.2. Consumer Genomics
12.5.3.2. Spain Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.3.2.1. Cardiovascular Diseases
12.5.3.2.2. Pregnancy care
12.5.3.2.3. Breast and Ovarian Cancer
12.5.3.2.4. Prostate cancer
12.5.3.2.5. Colon Cancer
12.5.3.2.6. Neurogenetics
12.5.3.2.7. Ocular Diseases
12.5.3.2.8. Diabetic Screening and Monitoring
12.5.3.2.9. Hereditary Cancer
12.5.3.2.10.
Others
12.5.3.3. Spain Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
12.5.3.3.1. Direct to Consumer (DTC)
12.5.3.3.2. Clinics
12.5.3.3.3. Hospitals
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1. Germany Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.4.1.1. Predictive Testing
12.5.4.1.1.1. Presymptomatic
Testing
12.5.4.1.1.2. Predispositional
Testing
12.5.4.1.2. Consumer Genomics
12.5.4.2. Germany Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.4.2.1. Cardiovascular Diseases
12.5.4.2.2. Pregnancy care
12.5.4.2.3. Breast and Ovarian Cancer
12.5.4.2.4. Prostate cancer
12.5.4.2.5. Colon Cancer
12.5.4.2.6. Neurogenetics
12.5.4.2.7. Ocular Diseases
12.5.4.2.8. Diabetic Screening and Monitoring
12.5.4.2.9. Hereditary Cancer
12.5.4.2.10.
Others
12.5.4.3. Germany Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
12.5.4.3.1. Direct to Consumer (DTC)
12.5.4.3.2. Clinics
12.5.4.3.3. Hospitals
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1. Italy Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
12.5.5.1.1. Predictive Testing
12.5.5.1.1.1. Presymptomatic
Testing
12.5.5.1.1.2. Predispositional
Testing
12.5.5.1.2. Consumer Genomics
12.5.5.2. Italy Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.5.2.1. Cardiovascular Diseases
12.5.5.2.2. Pregnancy care
12.5.5.2.3. Breast and Ovarian Cancer
12.5.5.2.4. Prostate cancer
12.5.5.2.5. Colon Cancer
12.5.5.2.6. Neurogenetics
12.5.5.2.7. Ocular Diseases
12.5.5.2.8. Diabetic Screening and Monitoring
12.5.5.2.9. Hereditary Cancer
12.5.5.2.10.
Others
12.5.5.3. Italy Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
12.5.5.3.1. Direct to Consumer (DTC)
12.5.5.3.2. Clinics
12.5.5.3.3. Hospitals
12.5.5.3.4. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic Countries Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.6.1.1. Predictive Testing
12.5.6.1.1.1. Presymptomatic
Testing
12.5.6.1.1.2. Predispositional
Testing
12.5.6.1.2. Consumer Genomics
12.5.6.2. Nordic Countries Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.6.2.1. Cardiovascular Diseases
12.5.6.2.2. Pregnancy care
12.5.6.2.3. Breast and Ovarian Cancer
12.5.6.2.4. Prostate cancer
12.5.6.2.5. Colon Cancer
12.5.6.2.6. Neurogenetics
12.5.6.2.7. Ocular Diseases
12.5.6.2.8. Diabetic Screening and Monitoring
12.5.6.2.9. Hereditary Cancer
12.5.6.2.10.
Others
12.5.6.3. Nordic Countries Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
12.5.6.3.1. Direct to Consumer (DTC)
12.5.6.3.2. Clinics
12.5.6.3.3. Hospitals
12.5.6.3.4. Others
12.5.6.4. Nordic Countries Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux Union Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.7.1.1. Predictive Testing
12.5.7.1.1.1. Presymptomatic
Testing
12.5.7.1.1.2. Predispositional
Testing
12.5.7.1.2. Consumer Genomics
12.5.7.2. Benelux Union Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.7.2.1. Cardiovascular Diseases
12.5.7.2.2. Pregnancy care
12.5.7.2.3. Breast and Ovarian Cancer
12.5.7.2.4. Prostate cancer
12.5.7.2.5. Colon Cancer
12.5.7.2.6. Neurogenetics
12.5.7.2.7. Ocular Diseases
12.5.7.2.8. Diabetic Screening and Monitoring
12.5.7.2.9. Hereditary Cancer
12.5.7.2.10.
Others
12.5.7.3. Benelux Union Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
12.5.7.3.1. Direct to Consumer (DTC)
12.5.7.3.2. Clinics
12.5.7.3.3. Hospitals
12.5.7.3.4. Others
12.5.7.4. Benelux Union Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest of Europe Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
12.5.8.1.1. Predictive Testing
12.5.8.1.1.1. Presymptomatic
Testing
12.5.8.1.1.2. Predispositional
Testing
12.5.8.1.2. Consumer Genomics
12.5.8.2. Rest of Europe Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.8.2.1. Cardiovascular Diseases
12.5.8.2.2. Pregnancy care
12.5.8.2.3. Breast and Ovarian Cancer
12.5.8.2.4. Prostate cancer
12.5.8.2.5. Colon Cancer
12.5.8.2.6. Neurogenetics
12.5.8.2.7. Ocular Diseases
12.5.8.2.8. Diabetic Screening and Monitoring
12.5.8.2.9. Hereditary Cancer
12.5.8.2.10.
Others
12.5.8.3. Rest of Europe Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
12.5.8.3.1. Direct to Consumer (DTC)
12.5.8.3.2. Clinics
12.5.8.3.3. Hospitals
12.5.8.3.4. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By Type
12.6.3. By
Application
12.6.4. By
Setting Type
13. Asia Pacific Predictive Genetic Testing And Consumer
Genomics Market Analysis and Forecasts,
2022 - 2030
13.1. Overview
13.1.1. Asia
Pacific Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn)
13.2. Asia
Pacific Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
13.2.1. Predictive
Testing
13.2.1.1. Presymptomatic Testing
13.2.1.2. Predispositional Testing
13.2.2. Consumer
Genomics
13.3. Asia Pacific
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
13.3.1. Cardiovascular
Diseases
13.3.2. Pregnancy
care
13.3.3. Breast
and Ovarian Cancer
13.3.4. Prostate
cancer
13.3.5. Colon
Cancer
13.3.6. Neurogenetics
13.3.7. Ocular
Diseases
13.3.8. Diabetic
Screening and Monitoring
13.3.9. Hereditary
Cancer
13.3.10. Others
13.4. Asia
Pacific Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
13.4.1. Direct
to Consumer (DTC)
13.4.2. Clinics
13.4.3. Hospitals
13.4.4. Others
13.5. Asia
Pacific Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.1. China
13.5.1.1. China Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.1.1.1. Predictive Testing
13.5.1.1.1.1. Presymptomatic
Testing
13.5.1.1.1.2. Predispositional
Testing
13.5.1.1.2. Consumer Genomics
13.5.1.2. China Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.1.2.1. Cardiovascular Diseases
13.5.1.2.2. Pregnancy care
13.5.1.2.3. Breast and Ovarian Cancer
13.5.1.2.4. Prostate cancer
13.5.1.2.5. Colon Cancer
13.5.1.2.6. Neurogenetics
13.5.1.2.7. Ocular Diseases
13.5.1.2.8. Diabetic Screening and Monitoring
13.5.1.2.9. Hereditary Cancer
13.5.1.2.10.
Others
13.5.1.3. China Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
13.5.1.3.1. Direct to Consumer (DTC)
13.5.1.3.2. Clinics
13.5.1.3.3. Hospitals
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1. Japan Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.2.1.1. Predictive Testing
13.5.2.1.1.1. Presymptomatic
Testing
13.5.2.1.1.2. Predispositional
Testing
13.5.2.1.2. Consumer Genomics
13.5.2.2. Japan Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.2.2.1. Cardiovascular Diseases
13.5.2.2.2. Pregnancy care
13.5.2.2.3. Breast and Ovarian Cancer
13.5.2.2.4. Prostate cancer
13.5.2.2.5. Colon Cancer
13.5.2.2.6. Neurogenetics
13.5.2.2.7. Ocular Diseases
13.5.2.2.8. Diabetic Screening and Monitoring
13.5.2.2.9. Hereditary Cancer
13.5.2.2.10.
Others
13.5.2.3. Japan Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
13.5.2.3.1. Direct to Consumer (DTC)
13.5.2.3.2. Clinics
13.5.2.3.3. Hospitals
13.5.2.3.4. Others
13.5.3. India
13.5.3.1. India Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
13.5.3.1.1. Predictive Testing
13.5.3.1.1.1. Presymptomatic
Testing
13.5.3.1.1.2. Predispositional
Testing
13.5.3.1.2. Consumer Genomics
13.5.3.2. India Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.3.2.1. Cardiovascular Diseases
13.5.3.2.2. Pregnancy care
13.5.3.2.3. Breast and Ovarian Cancer
13.5.3.2.4. Prostate cancer
13.5.3.2.5. Colon Cancer
13.5.3.2.6. Neurogenetics
13.5.3.2.7. Ocular Diseases
13.5.3.2.8. Diabetic Screening and Monitoring
13.5.3.2.9. Hereditary Cancer
13.5.3.2.10.
Others
13.5.3.3. India Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
13.5.3.3.1. Direct to Consumer (DTC)
13.5.3.3.2. Clinics
13.5.3.3.3. Hospitals
13.5.3.3.4. Others
13.5.4. New
Zealand
13.5.4.1. New Zealand Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.4.1.1. Predictive Testing
13.5.4.1.1.1. Presymptomatic
Testing
13.5.4.1.1.2. Predispositional
Testing
13.5.4.1.2. Consumer Genomics
13.5.4.2. New Zealand Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and Forecasts,
By Application
13.5.4.2.1. Cardiovascular Diseases
13.5.4.2.2. Pregnancy care
13.5.4.2.3. Breast and Ovarian Cancer
13.5.4.2.4. Prostate cancer
13.5.4.2.5. Colon Cancer
13.5.4.2.6. Neurogenetics
13.5.4.2.7. Ocular Diseases
13.5.4.2.8. Diabetic Screening and Monitoring
13.5.4.2.9. Hereditary Cancer
13.5.4.2.10.
Others
13.5.4.3. New Zealand Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
13.5.4.3.1. Direct to Consumer (DTC)
13.5.4.3.2. Clinics
13.5.4.3.3. Hospitals
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1. Australia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.5.1.1. Predictive Testing
13.5.5.1.1.1. Presymptomatic
Testing
13.5.5.1.1.2. Predispositional
Testing
13.5.5.1.2. Consumer Genomics
13.5.5.2. Australia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.5.2.1. Cardiovascular Diseases
13.5.5.2.2. Pregnancy care
13.5.5.2.3. Breast and Ovarian Cancer
13.5.5.2.4. Prostate cancer
13.5.5.2.5. Colon Cancer
13.5.5.2.6. Neurogenetics
13.5.5.2.7. Ocular Diseases
13.5.5.2.8. Diabetic Screening and Monitoring
13.5.5.2.9. Hereditary Cancer
13.5.5.2.10.
Others
13.5.5.3. Australia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
13.5.5.3.1. Direct to Consumer (DTC)
13.5.5.3.2. Clinics
13.5.5.3.3. Hospitals
13.5.5.3.4. Others
13.5.6. South
Korea
13.5.6.1. South Korea Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.6.1.1. Predictive Testing
13.5.6.1.1.1. Presymptomatic
Testing
13.5.6.1.1.2. Predispositional
Testing
13.5.6.1.2. Consumer Genomics
13.5.6.2. South Korea Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.6.2.1. Cardiovascular Diseases
13.5.6.2.2. Pregnancy care
13.5.6.2.3. Breast and Ovarian Cancer
13.5.6.2.4. Prostate cancer
13.5.6.2.5. Colon Cancer
13.5.6.2.6. Neurogenetics
13.5.6.2.7. Ocular Diseases
13.5.6.2.8. Diabetic Screening and Monitoring
13.5.6.2.9. Hereditary Cancer
13.5.6.2.10.
Others
13.5.6.3. South Korea Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
13.5.6.3.1. Direct to Consumer (DTC)
13.5.6.3.2. Clinics
13.5.6.3.3. Hospitals
13.5.6.3.4. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast Asia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.7.1.1. Predictive Testing
13.5.7.1.1.1. Presymptomatic
Testing
13.5.7.1.1.2. Predispositional
Testing
13.5.7.1.2. Consumer Genomics
13.5.7.2. Southeast Asia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.7.2.1. Cardiovascular Diseases
13.5.7.2.2. Pregnancy care
13.5.7.2.3. Breast and Ovarian Cancer
13.5.7.2.4. Prostate cancer
13.5.7.2.5. Colon Cancer
13.5.7.2.6. Neurogenetics
13.5.7.2.7. Ocular Diseases
13.5.7.2.8. Diabetic Screening and Monitoring
13.5.7.2.9. Hereditary Cancer
13.5.7.2.10.
Others
13.5.7.3. Southeast Asia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
13.5.7.3.1. Direct to Consumer (DTC)
13.5.7.3.2. Clinics
13.5.7.3.3. Hospitals
13.5.7.3.4. Others
13.5.7.4. Southeast Asia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest of Asia Pacific Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
13.5.8.1.1. Predictive Testing
13.5.8.1.1.1. Presymptomatic
Testing
13.5.8.1.1.2. Predispositional
Testing
13.5.8.1.2. Consumer Genomics
13.5.8.2. Rest of Asia Pacific Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.8.2.1. Cardiovascular Diseases
13.5.8.2.2. Pregnancy care
13.5.8.2.3. Breast and Ovarian Cancer
13.5.8.2.4. Prostate cancer
13.5.8.2.5. Colon Cancer
13.5.8.2.6. Neurogenetics
13.5.8.2.7. Ocular Diseases
13.5.8.2.8. Diabetic Screening and Monitoring
13.5.8.2.9. Hereditary Cancer
13.5.8.2.10.
Others
13.5.8.3. Rest of Asia Pacific Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
13.5.8.3.1. Direct to Consumer (DTC)
13.5.8.3.2. Clinics
13.5.8.3.3. Hospitals
13.5.8.3.4. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By Type
13.6.3. By
Application
13.6.4. By
Setting Type
14. Middle East and Africa Predictive Genetic Testing And
Consumer Genomics Market Analysis and
Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle
East and Africa Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn)
14.2. Middle
East and Africa Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
14.2.1. Predictive
Testing
14.2.1.1. Presymptomatic Testing
14.2.1.2. Predispositional Testing
14.2.2. Consumer
Genomics
14.3. Middle
East and Africa Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
14.3.1. Cardiovascular
Diseases
14.3.2. Pregnancy
care
14.3.3. Breast
and Ovarian Cancer
14.3.4. Prostate
cancer
14.3.5. Colon
Cancer
14.3.6. Neurogenetics
14.3.7. Ocular
Diseases
14.3.8. Diabetic
Screening and Monitoring
14.3.9. Hereditary
Cancer
14.3.10. Others
14.4. Middle
East and Africa Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
14.4.1. Direct
to Consumer (DTC)
14.4.2. Clinics
14.4.3. Hospitals
14.4.4. Others
14.5. Middle
East and Africa Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi Arabia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.1.1.1. Predictive Testing
14.5.1.1.1.1. Presymptomatic
Testing
14.5.1.1.1.2. Predispositional
Testing
14.5.1.1.2. Consumer Genomics
14.5.1.2. Saudi Arabia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.1.2.1. Cardiovascular Diseases
14.5.1.2.2. Pregnancy care
14.5.1.2.3. Breast and Ovarian Cancer
14.5.1.2.4. Prostate cancer
14.5.1.2.5. Colon Cancer
14.5.1.2.6. Neurogenetics
14.5.1.2.7. Ocular Diseases
14.5.1.2.8. Diabetic Screening and Monitoring
14.5.1.2.9. Hereditary Cancer
14.5.1.2.10.
Others
14.5.1.3. Saudi Arabia Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
14.5.1.3.1. Direct to Consumer (DTC)
14.5.1.3.2. Clinics
14.5.1.3.3. Hospitals
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1. UAE Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.2.1.1. Predictive Testing
14.5.2.1.1.1. Presymptomatic
Testing
14.5.2.1.1.2. Predispositional
Testing
14.5.2.1.2. Consumer Genomics
14.5.2.2. UAE Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.2.2.1. Cardiovascular Diseases
14.5.2.2.2. Pregnancy care
14.5.2.2.3. Breast and Ovarian Cancer
14.5.2.2.4. Prostate cancer
14.5.2.2.5. Colon Cancer
14.5.2.2.6. Neurogenetics
14.5.2.2.7. Ocular Diseases
14.5.2.2.8. Diabetic Screening and Monitoring
14.5.2.2.9. Hereditary Cancer
14.5.2.2.10.
Others
14.5.2.3. UAE Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
14.5.2.3.1. Direct to Consumer (DTC)
14.5.2.3.2. Clinics
14.5.2.3.3. Hospitals
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1. Egypt Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.3.1.1. Predictive Testing
14.5.3.1.1.1. Presymptomatic
Testing
14.5.3.1.1.2. Predispositional
Testing
14.5.3.1.2. Consumer Genomics
14.5.3.2. Egypt Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.3.2.1. Cardiovascular Diseases
14.5.3.2.2. Pregnancy care
14.5.3.2.3. Breast and Ovarian Cancer
14.5.3.2.4. Prostate cancer
14.5.3.2.5. Colon Cancer
14.5.3.2.6. Neurogenetics
14.5.3.2.7. Ocular Diseases
14.5.3.2.8. Diabetic Screening and Monitoring
14.5.3.2.9. Hereditary Cancer
14.5.3.2.10.
Others
14.5.3.3. Egypt Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
14.5.3.3.1. Direct to Consumer (DTC)
14.5.3.3.2. Clinics
14.5.3.3.3. Hospitals
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
14.5.4.1.1. Predictive Testing
14.5.4.1.1.1. Presymptomatic
Testing
14.5.4.1.1.2. Predispositional
Testing
14.5.4.1.2. Consumer Genomics
14.5.4.2. Kuwait Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.4.2.1. Cardiovascular Diseases
14.5.4.2.2. Pregnancy care
14.5.4.2.3. Breast and Ovarian Cancer
14.5.4.2.4. Prostate cancer
14.5.4.2.5. Colon Cancer
14.5.4.2.6. Neurogenetics
14.5.4.2.7. Ocular Diseases
14.5.4.2.8. Diabetic Screening and Monitoring
14.5.4.2.9. Hereditary Cancer
14.5.4.2.10.
Others
14.5.4.3. Kuwait Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
14.5.4.3.1. Direct to Consumer (DTC)
14.5.4.3.2. Clinics
14.5.4.3.3. Hospitals
14.5.4.3.4. Others
14.5.5. South
Africa
14.5.5.1. South Africa Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
14.5.5.1.1. Predictive Testing
14.5.5.1.1.1. Presymptomatic
Testing
14.5.5.1.1.2. Predispositional
Testing
14.5.5.1.2. Consumer Genomics
14.5.5.2. South Africa Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.5.2.1. Cardiovascular Diseases
14.5.5.2.2. Pregnancy care
14.5.5.2.3. Breast and Ovarian Cancer
14.5.5.2.4. Prostate cancer
14.5.5.2.5. Colon Cancer
14.5.5.2.6. Neurogenetics
14.5.5.2.7. Ocular Diseases
14.5.5.2.8. Diabetic Screening and Monitoring
14.5.5.2.9. Hereditary Cancer
14.5.5.2.10.
Others
14.5.5.3. South Africa Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
14.5.5.3.1. Direct to Consumer (DTC)
14.5.5.3.2. Clinics
14.5.5.3.3. Hospitals
14.5.5.3.4. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Predictive Genetic Testing
And Consumer Genomics Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.6.1.1. Predictive Testing
14.5.6.1.1.1. Presymptomatic
Testing
14.5.6.1.1.2. Predispositional
Testing
14.5.6.1.2. Consumer Genomics
14.5.6.2. Rest of Middle East & Africa Predictive Genetic Testing
And Consumer Genomics Market Revenue
(US$ Mn) and Forecasts, By Application
14.5.6.2.1. Cardiovascular Diseases
14.5.6.2.2. Pregnancy care
14.5.6.2.3. Breast and Ovarian Cancer
14.5.6.2.4. Prostate cancer
14.5.6.2.5. Colon Cancer
14.5.6.2.6. Neurogenetics
14.5.6.2.7. Ocular Diseases
14.5.6.2.8. Diabetic Screening and Monitoring
14.5.6.2.9. Hereditary Cancer
14.5.6.2.10.
Others
14.5.6.3. Rest of Middle East & Africa Predictive Genetic Testing
And Consumer Genomics Market Revenue
(US$ Mn) and Forecasts, By Setting Type
14.5.6.3.1. Direct to Consumer (DTC)
14.5.6.3.2. Clinics
14.5.6.3.3. Hospitals
14.5.6.3.4. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By Type
14.6.3. By
Application
14.6.4. By
Setting Type
15. Latin America Predictive Genetic Testing And Consumer
Genomics Market Analysis and Forecasts,
2022 - 2030
15.1. Overview
15.1.1. Latin America
Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn)
15.2. Latin
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
15.2.1. Predictive
Testing
15.2.1.1. Presymptomatic Testing
15.2.1.2. Predispositional Testing
15.2.2. Consumer
Genomics
15.3. Latin
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
15.3.1. Cardiovascular
Diseases
15.3.2. Pregnancy
care
15.3.3. Breast
and Ovarian Cancer
15.3.4. Prostate
cancer
15.3.5. Colon
Cancer
15.3.6. Neurogenetics
15.3.7. Ocular
Diseases
15.3.8. Diabetic
Screening and Monitoring
15.3.9. Hereditary
Cancer
15.3.10. Others
15.4. Latin
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
15.4.1. Direct
to Consumer (DTC)
15.4.2. Clinics
15.4.3. Hospitals
15.4.4. Others
15.5. Latin
America Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Country
15.5.1. Brazil
15.5.1.1. Brazil Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Type
15.5.1.1.1. Predictive Testing
15.5.1.1.1.1. Presymptomatic
Testing
15.5.1.1.1.2. Predispositional
Testing
15.5.1.1.2. Consumer Genomics
15.5.1.2. Brazil Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.1.2.1. Cardiovascular Diseases
15.5.1.2.2. Pregnancy care
15.5.1.2.3. Breast and Ovarian Cancer
15.5.1.2.4. Prostate cancer
15.5.1.2.5. Colon Cancer
15.5.1.2.6. Neurogenetics
15.5.1.2.7. Ocular Diseases
15.5.1.2.8. Diabetic Screening and Monitoring
15.5.1.2.9. Hereditary Cancer
15.5.1.2.10.
Others
15.5.1.3. Brazil Predictive Genetic Testing And Consumer Genomics Market Revenue (US$ Mn) and Forecasts, By
Setting Type
15.5.1.3.1. Direct to Consumer (DTC)
15.5.1.3.2. Clinics
15.5.1.3.3. Hospitals
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1. Argentina Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
15.5.2.1.1. Predictive Testing
15.5.2.1.1.1. Presymptomatic
Testing
15.5.2.1.1.2. Predispositional
Testing
15.5.2.1.2. Consumer Genomics
15.5.2.2. Argentina Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.2.2.1. Cardiovascular Diseases
15.5.2.2.2. Pregnancy care
15.5.2.2.3. Breast and Ovarian Cancer
15.5.2.2.4. Prostate cancer
15.5.2.2.5. Colon Cancer
15.5.2.2.6. Neurogenetics
15.5.2.2.7. Ocular Diseases
15.5.2.2.8. Diabetic Screening and Monitoring
15.5.2.2.9. Hereditary Cancer
15.5.2.2.10.
Others
15.5.2.3. Argentina Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
15.5.2.3.1. Direct to Consumer (DTC)
15.5.2.3.2. Clinics
15.5.2.3.3. Hospitals
15.5.2.3.4. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest of Latin America Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Type
15.5.3.1.1. Predictive Testing
15.5.3.1.1.1. Presymptomatic
Testing
15.5.3.1.1.2. Predispositional
Testing
15.5.3.1.2. Consumer Genomics
15.5.3.2. Rest of Latin America Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.3.2.1. Cardiovascular Diseases
15.5.3.2.2. Pregnancy care
15.5.3.2.3. Breast and Ovarian Cancer
15.5.3.2.4. Prostate cancer
15.5.3.2.5. Colon Cancer
15.5.3.2.6. Neurogenetics
15.5.3.2.7. Ocular Diseases
15.5.3.2.8. Diabetic Screening and Monitoring
15.5.3.2.9. Hereditary Cancer
15.5.3.2.10.
Others
15.5.3.3. Rest of Latin America Predictive Genetic Testing And Consumer
Genomics Market Revenue (US$ Mn) and
Forecasts, By Setting Type
15.5.3.3.1. Direct to Consumer (DTC)
15.5.3.3.2. Clinics
15.5.3.3.3. Hospitals
15.5.3.3.4. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By Type
15.6.3. By
Application
15.6.4. By
Setting Type
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2021
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. 23andMe,
Inc.
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Abbott
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Agilent
Technologies, Inc.
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Avellino.com
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. BGI
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Color
Health, Inc.
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. F.
Hoffmann-La Roche Ltd
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Gene by
Gene, Ltd.
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Illumina,
Inc.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Labcorp.
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Mapmygenome
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Myriad
Genetics, Inc.
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. Quest
Diagnostics, Inc.
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. Thermo
Fisher Scientific
17.14.1. Company
Details
17.14.2. Company
Overview
17.14.3. Product
Offerings
17.14.4. Key
Developments
17.14.5. Financial
Analysis
17.14.6. SWOT
Analysis
17.14.7. Business Strategies
17.15. Other
market participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
